Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Super-Affinity Antibody

Anti-Human CD85j/LILRB1/ILT2 Antibody (SAA0402), APC

Catalog #:   FHJ26413 Specific References (100) DATASHEET
Host species: Mouse
Isotype: IgG2a, kappa
Applications: ELISA, FCM
Accession: Q8NHL6
Overview

Catalog No.

FHJ26413

Species reactivity

Human

Host species

Mouse

Isotype

IgG2a, kappa

Clonality

Monoclonal

Conjugation

APC

Target

LIR1, Immunoglobulin-like transcript 2, MIR7, CD85 antigen-like family member J, Monocyte/macrophage immunoglobulin-like receptor 7, ILT-2, Leukocyte immunoglobulin-like receptor subfamily B member 1, LIR-1, CD85j, ILT2, LILRB1, MIR-7, Leukocyte immunoglobulin-like receptor 1

Concentration

0.5 mg/ml

Endotoxin level

Please contact with the lab for this information.

Accession

Q8NHL6

Applications

ELISA, FCM

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300.

Stability and Storage

Store at 4°C for 12 months. Protect from light. Do not freeze.

Clone ID

SAA0402

Data Image
References

Peripheral monocyte subsets are altered during gestation in oocyte donation pregnancy complicated with pre-eclampsia., PMID:39920890

Peripheral monocyte subsets are altered during gestation in oocyte donation pregnancy complicated with pre-eclampsia., PMID:39920890

MHC1/LILRB1 axis as an innate immune checkpoint for cancer therapy., PMID:38911856

MHC1/LILRB1 axis as an innate immune checkpoint for cancer therapy., PMID:38911856

Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer., PMID:37781391

Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer., PMID:37781391

Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages., PMID:36389667

Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages., PMID:36389667

Different classes of genomic inserts contribute to human antibody diversity., PMID:36037353

Different classes of genomic inserts contribute to human antibody diversity., PMID:36037353

Natural killer cell profiles in recurrent pregnancy loss: Increased expression and positive associations with TACTILE and LILRB1., PMID:36004818

Natural killer cell profiles in recurrent pregnancy loss: Increased expression and positive associations with TACTILE and LILRB1., PMID:36004818

Changes in the natural killer cell repertoire and function induced by the cancer immune adjuvant candidate IMMUNEPOTENT-CRP., PMID:35381435

Changes in the natural killer cell repertoire and function induced by the cancer immune adjuvant candidate IMMUNEPOTENT-CRP., PMID:35381435

HLA-G-ILT2 interaction contributes to suppression of bone marrow B cell proliferation in acquired aplastic anemia., PMID:35041051

HLA-G-ILT2 interaction contributes to suppression of bone marrow B cell proliferation in acquired aplastic anemia., PMID:35041051

LIR-1 educates expanded human NK cells and defines a unique antitumor NK cell subset with potent antibody-dependent cellular cytotoxicity., PMID:34631057

LIR-1 educates expanded human NK cells and defines a unique antitumor NK cell subset with potent antibody-dependent cellular cytotoxicity., PMID:34631057

Tumor infiltrating and peripheral CD4+ILT2+ T cells are a cytotoxic subset selectively inhibited by HLA-G in clear cell renal cell carcinoma patients., PMID:34186161

Tumor infiltrating and peripheral CD4+ILT2+ T cells are a cytotoxic subset selectively inhibited by HLA-G in clear cell renal cell carcinoma patients., PMID:34186161

First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G., PMID:33737343

First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G., PMID:33737343

ANGPTL2 Induces Synovial Inflammation via LILRB2., PMID:33538932

ANGPTL2 Induces Synovial Inflammation via LILRB2., PMID:33538932

The Molecular and Functional Characteristics of HLA-G and the Interaction with Its Receptors: Where to Intervene for Cancer Immunotherapy?, PMID:33213057

The Molecular and Functional Characteristics of HLA-G and the Interaction with Its Receptors: Where to Intervene for Cancer Immunotherapy?, PMID:33213057

Leukocyte immunoglobulin-like receptor subfamily B member 1 potentially acts as a diagnostic and prognostic target in certain subtypes of adenocarcinoma., PMID:32534335

Leukocyte immunoglobulin-like receptor subfamily B member 1 potentially acts as a diagnostic and prognostic target in certain subtypes of adenocarcinoma., PMID:32534335

Drug screening and identification of key candidate genes and pathways of rheumatoid arthritis., PMID:32468016

Drug screening and identification of key candidate genes and pathways of rheumatoid arthritis., PMID:32468016

Cytometry-based analysis of HLA-G functions according to ILT2 expression., PMID:32081570

Cytometry-based analysis of HLA-G functions according to ILT2 expression., PMID:32081570

Bioinformatics analyses on the immune status of renal transplant patients, a systemic research of renal transplantation., PMID:32046717

Bioinformatics analyses on the immune status of renal transplant patients, a systemic research of renal transplantation., PMID:32046717

Structures of the four Ig-like domain LILRB2 and the four-domain LILRB1 and HLA-G1 complex., PMID:31273318

Structures of the four Ig-like domain LILRB2 and the four-domain LILRB1 and HLA-G1 complex., PMID:31273318

The MHC class I-LILRB1 signalling axis as a promising target in cancer therapy., PMID:31267559

The MHC class I-LILRB1 signalling axis as a promising target in cancer therapy., PMID:31267559

LILRB1 Blockade Enhances Bispecific T Cell Engager Antibody-Induced Tumor Cell Killing by Effector CD8+ T Cells., PMID:31253728

LILRB1 Blockade Enhances Bispecific T Cell Engager Antibody-Induced Tumor Cell Killing by Effector CD8+ T Cells., PMID:31253728

Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia., PMID:30619281

Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia., PMID:30619281

Characterization of Natural Killer Cells in HIV Patients Beginning Therapy with a High Burden of Cytomegalovirus., PMID:30422022

Characterization of Natural Killer Cells in HIV Patients Beginning Therapy with a High Burden of Cytomegalovirus., PMID:30422022

Inhibiting HLA-G restores IFN-γ and TNF-α producing T cell in pleural Tuberculosis., PMID:29559123

Inhibiting HLA-G restores IFN-γ and TNF-α producing T cell in pleural Tuberculosis., PMID:29559123

CMV drives the expansion of highly functional memory T cells expressing NK-cell receptors in renal transplant recipients., PMID:28586095

CMV drives the expansion of highly functional memory T cells expressing NK-cell receptors in renal transplant recipients., PMID:28586095

Cytomegalovirus infection alters phenotypes of different γδ T-cell subsets in renal transplant recipients with long-term stable graft function., PMID:28198539

Cytomegalovirus infection alters phenotypes of different γδ T-cell subsets in renal transplant recipients with long-term stable graft function., PMID:28198539

Dengue virus compartmentalization during antibody-enhanced infection., PMID:28084461

Dengue virus compartmentalization during antibody-enhanced infection., PMID:28084461

Asymptomatic CMV infections in long-term renal transplant recipients are associated with the loss of FcRγ from LIR-1+ NK cells., PMID:27562679

Asymptomatic CMV infections in long-term renal transplant recipients are associated with the loss of FcRγ from LIR-1+ NK cells., PMID:27562679

Phenotypic and Functional Dysregulated Blood NK Cells in Colorectal Cancer Patients Can Be Activated by Cetuximab Plus IL-2 or IL-15., PMID:27777574

Phenotypic and Functional Dysregulated Blood NK Cells in Colorectal Cancer Patients Can Be Activated by Cetuximab Plus IL-2 or IL-15., PMID:27777574

Leukocyte Ig-Like receptor B1 restrains dendritic cell function through increased expression of the NF-κB regulator ABIN1/TNIP1., PMID:27129285

Leukocyte Ig-Like receptor B1 restrains dendritic cell function through increased expression of the NF-κB regulator ABIN1/TNIP1., PMID:27129285

Multiplex bead-based immunoassay for the free soluble forms of the HLA-G receptors, ILT2 and ILT4., PMID:26874236

Multiplex bead-based immunoassay for the free soluble forms of the HLA-G receptors, ILT2 and ILT4., PMID:26874236

Latent Cytomegalovirus Infection in Rheumatoid Arthritis and Increased Frequencies of Cytolytic LIR-1+CD8+ T Cells., PMID:26314621

Latent Cytomegalovirus Infection in Rheumatoid Arthritis and Increased Frequencies of Cytolytic LIR-1+CD8+ T Cells., PMID:26314621

Overexpression of CD85j in TNBC patients inhibits Cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade., PMID:25726929

Overexpression of CD85j in TNBC patients inhibits Cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade., PMID:25726929

Leukocyte immunoglobulin-like receptor B1 is critical for antibody-dependent dengue., PMID:24550301

Leukocyte immunoglobulin-like receptor B1 is critical for antibody-dependent dengue., PMID:24550301

LILR-B1 blocks activating FcγR signaling to allow antibody dependent enhancement of dengue virus infection., PMID:24501131

LILR-B1 blocks activating FcγR signaling to allow antibody dependent enhancement of dengue virus infection., PMID:24501131

Crystal structures of the two membrane-proximal Ig-like domains (D3D4) of LILRB1/B2: alternative models for their involvement in peptide-HLA binding., PMID:23955630

Crystal structures of the two membrane-proximal Ig-like domains (D3D4) of LILRB1/B2: alternative models for their involvement in peptide-HLA binding., PMID:23955630

Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation., PMID:23818644

Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation., PMID:23818644

Defective expression and function of the ILT2/CD85j regulatory receptor in dendritic cells from patients with systemic lupus erythematosus., PMID:23756160

Defective expression and function of the ILT2/CD85j regulatory receptor in dendritic cells from patients with systemic lupus erythematosus., PMID:23756160

Autolysosomal β-catenin degradation regulates Wnt-autophagy-p62 crosstalk., PMID:23736261

Autolysosomal β-catenin degradation regulates Wnt-autophagy-p62 crosstalk., PMID:23736261

Cis association of leukocyte Ig-like receptor 1 with MHC class I modulates accessibility to antibodies and HCMV UL18., PMID:23348966

Cis association of leukocyte Ig-like receptor 1 with MHC class I modulates accessibility to antibodies and HCMV UL18., PMID:23348966

Impact of the NK cell receptor LIR-1 (ILT-2/CD85j/LILRB1) on cytotoxicity against multiple myeloma., PMID:22844324

Impact of the NK cell receptor LIR-1 (ILT-2/CD85j/LILRB1) on cytotoxicity against multiple myeloma., PMID:22844324

Inhibitory receptors are expressed by Trypanosoma cruzi-specific effector T cells and in hearts of subjects with chronic Chagas disease., PMID:22574131

Inhibitory receptors are expressed by Trypanosoma cruzi-specific effector T cells and in hearts of subjects with chronic Chagas disease., PMID:22574131

Analysis of immunoglobulin-like transcripts (ILTs) in lymphocytes with sHLA-G and IL10 from SLE patients., PMID:22562117

Analysis of immunoglobulin-like transcripts (ILTs) in lymphocytes with sHLA-G and IL10 from SLE patients., PMID:22562117

HLA-G inhibition of NK-cell cytolytic function is uncoupled from tumor cell lipid raft reorganization., PMID:22144141

HLA-G inhibition of NK-cell cytolytic function is uncoupled from tumor cell lipid raft reorganization., PMID:22144141

Lymphocyte cell-cycle inhibition by HLA-G is mediated by phosphatase SHP-2 and acts on the mTOR pathway., PMID:21887223

Lymphocyte cell-cycle inhibition by HLA-G is mediated by phosphatase SHP-2 and acts on the mTOR pathway., PMID:21887223

Association of atherosclerosis with expression of the LILRB1 receptor by human NK and T-cells supports the infectious burden hypothesis., PMID:21817101

Association of atherosclerosis with expression of the LILRB1 receptor by human NK and T-cells supports the infectious burden hypothesis., PMID:21817101

Up-regulation of cytolytic functions of human Vδ2-γ T lymphocytes through engagement of ILT2 expressed by tumor target cells., PMID:21233315

Up-regulation of cytolytic functions of human Vδ2-γ T lymphocytes through engagement of ILT2 expressed by tumor target cells., PMID:21233315

High affinity soluble ILT2 receptor: a potent inhibitor of CD8(+) T cell activation., PMID:21213105

High affinity soluble ILT2 receptor: a potent inhibitor of CD8(+) T cell activation., PMID:21213105

A novel mechanism of soluble HLA-G mediated immune modulation: downregulation of T cell chemokine receptor expression and impairment of chemotaxis., PMID:20668702

A novel mechanism of soluble HLA-G mediated immune modulation: downregulation of T cell chemokine receptor expression and impairment of chemotaxis., PMID:20668702

Leukocyte immunoglobulin-like receptors maintain unique antigen-presenting properties of circulating myeloid dendritic cells in HIV-1-infected elite controllers., PMID:20631139

Leukocyte immunoglobulin-like receptors maintain unique antigen-presenting properties of circulating myeloid dendritic cells in HIV-1-infected elite controllers., PMID:20631139

Natural killer receptors distribution in multiple sclerosis: Relation to clinical course and interferon-beta therapy., PMID:20580616

Natural killer receptors distribution in multiple sclerosis: Relation to clinical course and interferon-beta therapy., PMID:20580616

Datasheet
$ 292
Product specifications
50 T 292 100 T 484

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Human CD85j/LILRB1/ILT2 Antibody (SAA0402), APC [FHJ26413]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only